Efgartigimod has been approved in other countries as a treatment for adult patients with myasthenia gravis, a rare disease causing muscle weakness. However, efgartigimod is an experimental treatment in this study. This means that it is not an approved treatment for thyroid eye disease (TED) in Australia.

Efgartigimod may help improve TED. This is because efgartigimod may reduce the antibodies that cause symptoms in patients with TED.

This research project aims to look at the safety and efficacy of Efgartigimod in people with thyroid eye disease (TED). There is a 2 in 3 chance (approximately 67%) of participants receiving efgartigimod and a 1 in 3 chance of receiving placebo.

Participation in the study will last about 1 to 2 years depending on the individual’s response to the treatment. For further information about this study please contact the Clinical Trials Research Centre on (03) 9929 8076 or email info@ceruleaclinicaltrials.org.au